UBC Medical Indonesia Tbk. vs Trimegah Karya Pratama Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp148 (market cap 576.7B, 3.48M 24h volume), while Trimegah Karya Pratama Tbk. trades at Rp139 (market cap 272.02B, 55.79M 24h volume). The key difference: UBC Medical Indonesia Tbk. is far larger — about 2.1× Trimegah Karya Pratama Tbk.'s market cap, and Trimegah Karya Pratama Tbk. is more actively traded (55.79M versus 3.48M). Which is the better fit depends on your goals.
| LABS | UVCR | |
|---|---|---|
Market Cap | 576.7B | 272.02B |
Volume | 3.48M | 55.79M |
Lot | 34.82K | 557.94K |
Turnover | 522.79M | 7.75B |
Average Price | 150.13 | 138.88 |
Value | 522.79M | 7.75B |
Indicative Equilibrium Price | 148 | 139 |
Indicative Equilibrium Volume | 350 | 6.83K |
Trailing returns across standard periods
Latest headlines on both assets
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Read more on UVCR →